Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Veliparib improves PFS in high-grade serous epithelial ovarian cancer

Key clinical point: Adding veliparib to frontline chemotherapy and maintenance for high-grade serous epithelial ovarian cancer significantly extended progression-free survival.

Major finding: Median progression-free survival was 23.5 in the veliparib group versus 17.3 months in the control group.

Study details: The randomized, phase 3 VELIA/GOG-3005 trial of 1,140 patients.

Disclosures: The study was sponsored by AbbVie. Dr. Coleman and Dr. Oaknin reported relationships with numerous pharmaceutical companies.


Coleman RL et al. ESMO 2019, Abstract LBA3-PR.